Utility of the Skin Cancer Quality of Life Impact Tool

NACompletedINTERVENTIONAL
Enrollment

318

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

August 31, 2017

Study Completion Date

November 30, 2017

Conditions
Skin NeoplasmSquamous Cell CarcinomaBasal Cell Carcinoma
Interventions
OTHER

SCQOLIT questionnaire

"Participants will be invited to complete the SCQOLIT and EQ-5D (used for comparison purposes, given its widespread use in other healthcare contexts in the UK) questionnaires \[Appendices C \& D) at:~1. baseline (after histological diagnosis of a NMSC is confirmed - both Groups)~2. 3 months - either by postal (Group 1) or face-to-face (Group 2) dependent on whether the patient is returning to the Dermatology clinic for routine follow-up~3. at 6-9 months in the dermatology clinic if the patient is deemed high risk (squamous cell carcinoma with high risk clinicopathological features as listed by the National British Association Dermatologists Multiprofessional Guidelines for management of SCC) (Group 2 only)"

Trial Locations (1)

OX3 7LE

Churchill Hospital, Headington

All Listed Sponsors
collaborator

University of Oxford

OTHER

lead

Oxford University Hospitals NHS Trust

OTHER

NCT02580916 - Utility of the Skin Cancer Quality of Life Impact Tool | Biotech Hunter | Biotech Hunter